Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glufosfamide vs 5-FU in Metastatic Pancreatic Adenocarcinoma
NCT01954992Phase 3Recruiting
- Sponsor
- Eleison Pharmaceuticals
- Start
- Apr 2014
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of glufosfamide in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Eleison Pharmaceuticals. Primary endpoint: Overall Survival. Started Apr 2014; status: recruiting.
02
Drugs
glufosfamide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01954992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01954992.